On our screens:Cheap stocks by free cash flow yield
Is the price fair?
What DXCM's price assumes
Dexcom trades at 33.5× earnings against 30.9× for the median Medical Devices name, more expensive than its own group.
33.5
Trailing P/E · Medical Devices median 30.9 · 1.09× the median: the market pays up for this one
- Price / sales
- 5.13
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.0%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- +5.6%
Growth the price implies · The price pays for +5.6% free cash flow growth a year for a decade; the business has delivered +44% a year over the last three.
Details›
- Price / book2026-Q1
- 8.36
- Healthcare median P/E362 names
- 29.9
- Medical Devices median P/E39 names
- 30.9
- Free cash flow, trailing twelve months
- $1.41B
- Market capitalisation
- $28.0B
- 3-year revenue growth
- +16%
- 3-year free cash flow growth
- +44%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 30.9× today against a 81.8× median |
| 52-week range | $54.84 – $92.34 |
| Today | $84.49 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
The closest names by size in the same industry